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Chronic obstructive pulmonary disease (COPD) is frequently associated with chronic heart fail-
ure (CHF) or coronary artery disease (CAD). In spite of the recommendation to use beta-
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Heart failurediseases. To find out the prevalence of use of BB, 256 COPD patients were consecutively re-
cruited by pulmonary physicians from 14 hospitals in 7 regions of Spain in their outpatient of-
fices if they had a diagnosis of COPD, were not on long-term oxygen therapy, had CHF or CAD,
and met the criteria for BB treatment.
In patients with indication 58% (95%CI, 52e64%) of the COPD patients and 97% of the non-
COPD patients were on BB (p < 0.001). In patients with COPD, several factors were indepen-
dently related to at least one visit to the emergency room in the previous year such as use of
BB, adjusted OR Z 0.27 (95% CI 0.15e0.50), GOLD stage D, OR Z 2.52 (1.40e4.53), baseline
heart rate >70, OR 2.19 (1.24e3.86) use of long-acting beta2-agonists OR Z 2.18 (1.29
e3.68), previous episodes of left ventricular failure OR 2.27 (1.19e4.33) and diabetes,
OR Z 1.82 (1.08e3.38).
We conclude that, according to what is recommended by current guidelines, BB are still
under-prescribed in COPD patients. COPD patients with CHF or CAD using BB suffer fewer ex-
acerbations and visits to the ER. GOLD stage, use of long-acting beta2-agonists, baseline heart
rate and comorbidities are also risk factors for exacerbations in this population.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of morbi-mortality worldwide [1] and it is frequently
associated with a number of comorbidities [1]. Population
studies have shown that the prevalence of chronic heart
failure (CHF) in COPD patients ranges between 8% and 27%
[2,3] and for coronary artery disease (CAD) it is between
15% and 25% [2,3].When present, cardiac comorbidities
have a substantial negative impact on the survival of COPD
[4].
There is a bulk of evidence showing that the use of beta-
blockers (BB) increases survival in both patients with CHF
[5] and CAD [6]. “Post-hoc” analysis of the COPD pop-
ulations included in large trials on the use BB after acute
myocardial infarction [6] or CHF [3] suggest a protective
effect of these drugs in such patients. Moreover, there is
evidence showing the safety of using BB d especially car-
dioselective onesd in COPD [7].
In spite of the evidence and recommendation for their
use [1,8e10], BB are likely under-prescribed [3,11e15] to
patients with coexistent COPD and heart diseases. This is
largely due to concerns about precipitating respiratory
deterioration.
The two aims of this study were 1) to determine the
frequency of guidelines concordant BB use in COPD patients
assisted at outpatient clinics in 14 hospitals from 7 regions
of Spain and 2) to identify whether the use of BB was
related to frequent exacerbations (i.e 2 exacerbations)
the previous year or to severe exacerbations requiring an
emergency room (ER) visit.Methods
This is an analytical cross-sectional study. COPD patients
were consecutively recruited, by pulmonary physicians of
the participating hospitals in their outpatient offices be-
tween May 2012 and May 2013. Inclusion criteria were: a
previous diagnosis of COPD [1] and CHF or CAD made at
least one year earlier, criteria for BB treatment (i.e. leftventricular ejection fraction (LVEF) 40%, active coronary
heart disease or a previous acute myocardial infarction)
and no contraindications for BB treatment (heart
rate < 60 beats/min prior to treatment, symptomatic hy-
potension, evidence of significant fluid retention in patients
also treated with angiotensin converting enzyme inhibitors,
diuretics and salt restriction, signs of peripheral hypo-
perfusion, PR interval >0.24 s, second or third degree
atrioventricular block (except with pacemakers), history of
severe bronchospasm or peripheral arterial disease with
ischemia at rest). Patients were also excluded if they had
other chronic pulmonary conditions (interstitial disease,
asthma, cancer) or were on long-term oxygen therapy.
A concomitant cohort of patients diagnosed with CAD or
CHF, meeting the criteria for the use of BB mentioned
before and not known to have COPD, was also recruited in
the outpatient offices by cardiologists of the same centres
to compare the use of BB between COPD and non-COPD
patients.
Sample size was projected to achieve 5% accuracy in
estimating the frequency of BB use by a normal, bilateral
95%, asymptotic confidence interval for an anticipated
frequency of use of 70%, resulting in 268 patients needed to
be included. With this sample size, and the mentioned
proportion (i.e. 70%), differences of at least 12% could be
detected in the rate of exacerbation by means of bilateral
c2 with an alpha error of 5% and a statistical power of 0.8.
An additional sample of at least 59 non-COPD patients was
needed to detect differences of 20% in the proportion of
use of BB with an alpha error of 5% and a statically power of
0.9.
The study was approved by the clinical research ethical
committees of the participating hospitals and regions and
all patients signed an informed consent form.
Outcome measurements
The most recent spirometry, echocardiographic LVEF, EKG
and hemoglobin concentrations were obtained from the
medical records. Heart Rate (HR) was measured in the last
EKG available within the previous year with the patient on
Table 1 Comparison between COPD and non-COPD pa-
tients of some relevant variables. Mean (SD).
Variable COPD (n Z 256) Non-COPD
(n Z 101)
p
Female (%) 6.7 (1.5) 29 (4.5) 0.000
Age (years) 72.2 (8.9) 69.9 (11.8) 0.010
BMI (kg/m2) 29.5 (4.9) 28.0 (4.8) 0.018
LVEF (%) 43.7 (13.3) 38.8 (14.4) 0.011
packs-year 51.0 (24.3) 38.1 (20.0) 0.000
Active smoker (%) 14.1 (2.2) 15.1(3.5) 0.865
Hb (mg/dl) 13.1 (2.3) 11 (2.0) 0.102
Anemia (%) 28.7(2.8) 27.7 (4.5) 0.664
CHD (%) 74.6 (2.7) 86.1 (3.4) 0.023
LVF (%) 25.4 (2.7) 13.9 (3.4) 0.022
Systemic
hypertension
75.5 (2.7) 70.4 (4.5) 0.334
Diabetes (%) 37.4 (3.0) 36.6 (4.7) 0.892
Dyslipidemia (%) 58.1 (3.0) 73.3 (4.3) 0.007
HR (bpm) 78.1 (16.7) 71.2 (15.4) 0.001
BB (%) 58.2 (3.1) 97.0 (3.1) 0.000
Calcium
antagonists (%)
37.9 (3.0) 21.8 (4.1) 0.004
Female: female proportion, BMI: body mass index, LVEF: left
ventricular ejection fraction, Hb: blood hemoglobin concen-
tration, CHD: Coronary heart disease, LVF: history of left ven-
tricular failure episodes, HR: resting heart rate (beats per
minute), BB: on beta-blockers.
Figure 1 Differences in beta-blockers use between COPD
and non-COPD patients. BB: with beta-blocker treatment, No
BB: without beta-blocker treatment.
Beta-blockers use in COPD 739BB. The impact of the disease was measured by the COPD
Assessment Test (CATª, 2009 GlaxoSmithKline companies.
Last Updated: February 26, 2012). Use of cardiac and res-
piratory drugs, other comorbidities, exacerbations or ad-
missions were systematically obtained through direct
interviews and from the available medical records. Exac-
erbation was defined as any change in a previously stable
clinical state requiring health care resources (i.e unsched-
uled visits, changes in medication, or a visit to the ER).
Statistical analysis
Interval variables are expressed as mean and standard de-
viation within parenthesis, proportion are expressed with
their standard error within parenthesis. Interval variables
are compared by means of bilateral unpaired student t, and
proportions by means of bilateral c2. Multiple logistic re-
gressions were used to determine the variables related with
2 exacerbations in the previous year, and with exacer-
bations attended at the ER. Missing data for the variables
included in the initial model were excluded from the
analysis.
Results
Two hundred and fifty six COPD patients and 101 non-COPD
patients were included. Missing data for the variables
included in the initial model were random and not higher
than 1%. Patients in the COPD group were slightly older and
more overweight, had a history of more intense exposure to
cigarette smoke and in a higher proportion of them, heart
failure was the indication for BB. However, no differences
in LVEF were observed between both groups (Table 1). The
non-COPD group had a higher proportion of patients with a
history of coronary artery disease and of females (Table 1).
With regard to other risk factors; while the proportion of
patients with dyslipidemia was higher in the non-COPD
group, no differences were observed in the frequency of
systemic hypertension or diabetes (Table 1).
Only 148, 58% (95%CI, 52%e64%) of the COPD patients with
indication were on BB, while this proportion was 97% (94%e
100%) in the non-COPD group. With regard to other cardiac
drugs a significantly larger proportion of patients with COPD
were on calcium antagonists (Table 1). However, no differ-
enceswereobserved in theuseofother typeofdrugs including
angiotensin converting enzyme inhibitors, angiotensin re-
ceptor II antagonists, nitrites, diuretics, antiarrhythmic drugs,
aspirin, other antiplatelet drugs, oral anticoagulants, oral
antidiabetic drugs, insulin or lipid-lowering drugs.
When looking at the specific BB molecules, a larger
proportion of non-COPD patients were on atenolol while
bisoprolol was more prescribed to the COPD group (Fig. 1).
Nonetheless, the overall use of cardioselective BB was not
different (68% in the non-COPD group and 67% in the COPD
group).
We see small differences in several variables between
those on BB and those without them (Table 2) within the
COPD subgroup. The group of COPD patients on BB had a
larger proportion of subjects with several comorbidities
such as anemia, diabetes, systemic hypertension, over-
weight and history of acute episodes of left ventricularfailure. From a functional point of view, they had worse
cardiac function; however, they were less obstructive. In
spite of these facts, they were less symptomatic and had
suffered fewer exacerbations in the last year (Table 2).
Very few of our patients were in GOLD combined
assessment stage C (Table 3). Regarding the other stages, a
higher proportion of patients on BB belonged to stages A
and B and a lower proportion to stage D (Table 3).However,
only the differences in the latter were significant
(p < 0.026).
Table 2 Comparisons of some relevant variables between
COPD with and without beta-blockers. Mean (SD).
Variable BB (n Z 149) No BB
(n Z 107)
p
Female (%) 10.9 (2.6) 0.9 (29.9) 0.001
Age (years) 71.1 (9.6) 73.7 (7.9) 0.022
BMI (kg/m2) 30.2 (5.0) 28.5 (4.7) 0.020
LVEF (%) 41.7 (13.1) 50.7 (11.5) 0.011
packs-year 49.2 (23.8) 43.7 (13.3) 0.159
Active smoker (%) 17.6 (3.1) 10.2(2.9) 0.108
Anemia (%) 23.8 (3.5) 35.5(4.6) 0.000
Hb (mg/dl) 13.7 (2.0) 12.0 (2.6) 0.042
CAD (%) 72.3 (3.7) 77.8 (4.0) 0.383
LVF (%) 45.2 (4.1) 29.9 (4.4) 0.018
Systemic arterial
hypertension
82.2 (3.1) 66.4 (4.5) 0.005
Diabetes (%) 43.5 (4.1) 29.9 (4.4) 0.019
Dyslipidemia (%) 57.4 (4.1) 58.9 (4.7) 0.897
Overweight
(BMI > 29.9 kg/m2)
56.4 (4.1) 29.0 (4.4) 0.000
Systemic hypertension 82.3 (3.1) 66.0 (4.6) 0.000
Atrial fibrillation (%) 18.1 (3.1) 18.7 (3.7) 0.388
Dyspnea (mMRC) 2.2 (1.0) 2.51 (1.2) 0.011
CAT 16.2 (6.8) 18.1 (8.4) 0.046
N Exacerbations 1.25 (1.6) 1.65 (1.6) 0.135
N Exacerbations ER 0.65 (1.2) 1.12 (1.4) 0.092
Exacerbations 2 (%) 16.1 (3.0) 31.8 (4.5) 0.000
Exacerbations (ER) % 36.9 (3.9) 58.8 (4.7) 0.000
Exacerbaitions 2
or ER (%)
38.8 (4.0) 58.8 (4.7) 0.000
HR (bpm) 76.7 (14.9) 80.1 (18.8) 0.125
FEV1 %predicted 58.7 (16.9) 52.1 (18.4) 0.003
FVC %predicted 76.4 (19.6) 79.3 (22.7) 0.282
FEV1/FVC % 56.7 (10.4) 49.6 (11.5) 0.000
BB: On beta-blocker treatment, No BB: without beta-blocker
treatment, Female: female proportion, BMI: body mass index,
LVEF: left ventricular ejection fraction, Hb hemoglobin blood
concentration, CAD: Coronary artery disease, LVF: history of
left ventricular failure episodes, mMRC: Medical Research
Council modified scale, CAT: COPD assessment test, ER: exac-
erbations attended in the Emergency Room, HR: heart rate
(beats per minute),FEV1: forced expiratory volume in the first
second, FVC: forced vital capacity.
Table 3 Use of beta-blockers by Global Initiative for
Chronic Obstructive Lung disease risk assessment group
(GOLD) combined COPD assessment.
GOLD BB No BB All
N % N % N %
A 37 25% 21 20% 58 23%
B 65 44% 39 36% 104 41%
C 8 5% 5 5% 13 5%
D 39 26% 42 39% 81 32%
Total 149 107 256
BB: On beta-blocker treatment, No BB: without beta-blocker
treatment . “n” number. “%” column percentage, GOLD.
740 L. Puente-Maestu et al.With respect to respiratory medication (Fig. 2), it is
noteworthy that there was less overall use of long-acting
beta2-adrenergic drugs (LABA) and ultra-LABA (once a day
LABA) in those on BB. Moreover the use of LABA was also
different with a higher proportion of patients on ultra-LABA
and fewer patients on the more veteran LABAs. As LABA
were mostly used in fixed-dose combinations, less use of
inhaled corticosteroids was also found in COPD patients on
BB (Table 4). The overall use of inhaled anticholinergic
drugs (i.e. tiotropium and ipratropium as standalone long-
term anticholinergic drug) was also lower in the BB group
as compared with the non-BB group (Table 4).
Regarding other medications, patients on BB used more
vasodilators and diuretics.
Several of the studied factors (Table 5) were associated
with either 2 exacerbations or at least one exacerbations
attended at the ER in the previous year. In general terms,
these factors were lung function (i.e. FEV1 <50% predicted)
and symptoms either measured by the mMRC or the CATd
and consequently the GOLD combined assessment stages A
(lower risk) and D (higher risk) since they are directly
derived from themd use of BB, hypolipemiants and the
presence of comorbidities such as anemia, diabetes, atrial
fibrillation and previous episodes of LVF. Interestingly the
use of LABA dusually in combinations with inhaled corti-
costeroidsd were associated with a higher risk of exacer-
bation. Multiple linear regressions showed that BB
treatment, as well as being in GOLD combined risk assess-
ment stages D, were independent risk factors for both
multiple exacerbations and exacerbations attended at the
ER, while comorbidities and use of LABA were independent
factors increasing the risk of exacerbations attended at the
ER (Table 6).
Discussion
In spite of the evidence in favor [10,16,17], and guideline
recommendations [1,9,10], the proportion of COPD patients
with indication for BB drugs because of a heart disease, whoFigure 2 Differences in bronchodilators use between COPD
patients with and without beta-blockers. BB: with beta-blocker
treatment, No BB: without beta-blocker treatment.
Table 4 Use of drugs by COPD and non-COPD patients.
Mean (SD).
Variable BB (n Z 148) No-BB
(n Z 108)
p
Ca-antagonists (%) 38.5 (4.0) 37 (4.6) 0.896
ACE Inhibitors (%) 47.5 (4.1) 36.1 (4.6) 0.074
ARB (%) 32.4 (3.8) 32.4 (4.5) 0.383
Aspirin (%) 64.6 (3.9) 69.8 (4.4) 0.388
Anti-platelet agents (%) 37 (4.0) 32.7 (4.5) 0.482
Oral anticoagulants (%) 14.3 (2.9) 13.9 (3.3) 0.928
Lipid-lowering (%) 41.8 (4.1) 48.1 (4.8) 0.482
Diuretics (%) 30.6 3.8) 18.5 (3.7) 0.068
Antiarrhythmics (%) 11.6 (2.6) 9.3 (2.8) 0.023
Oral antidiabetics (%) 7.5 (4.0) 6.5 (2.4) 0.758
Insulin (%) 2.8 (2.2) 1.4 (1.1) 0.428
Rescue BD (%) 75.7 (3.5) 68.5 (4.5) 0.205
LABA (%) 52 (1.4) 76.9 (4.1) 0.000
ultra-LABA (%) 20.9 (4.1) 7.4 (2.5) 0.003
LABA þ U (%) 72.9 (3.3) 84.3 (3.5) 0.032
ICE (%) 55.4 (4.1) 77.8 (4.0) 0.000
LAMA (%) 71.6 (3.7) 80.4 (3.8) 0.101
LAMA þ SAMA (%) 76.4 (3.5) 83.6 (3.9) 0.009
Roflumilast (%) 4.1 (1.6) 9.3 (2.8) 0.092
Ca-antagonists: calcium channel blockers, ACE Inhibitors:
angiotensin converting enzyme inhibitors, ARB angiotensin-2
receptor blockers BD:bronchodilators, LABA: long-acting
beta2-agonists,LABA þ U: proportion of patients on LABA or
ultra-LABA. LAMA: long-acting antimuscarinic agent. SAMA:
short acting antimuscarining agent used as standalone chronic
antimuscarininc treatmet, ICE: inhaled corticosteroids.
Beta-blockers use in COPD 741are actually on BB in Spain is around 58%, while in patients
not believed to have COPD managed by cardiologist is 97%
(Table 1). The latter is about 15% higher than what has been
previously described in another Spanish outpatient popu-
lation of patients with heart conditions requiring these
drugs [18]. However, if patients with respiratory disease,
bradycardia, cognitive deterioration or difficulties for the
follow-up of the treatment are subtracted, as they were in
the present work, the figures of both studies are similarly
high [18].
There is very little previous information about the use of
BB in COPD in Spain or, as a matter of fact, in other Euro-
pean countries. In the candesartan in heart failure (CHARM)
study, patients were recruited between 1999 and 2001 from
26 countries of Asia, Europe dincluding Spaind North-
America, Oceania and South-Africa. Thirty two percent of
the patients receiving bronchodilators and 57.6% those
without bronchodilator therapy were on BB [3]. Separated
information for Spain was not provided though. In another
study in the Netherlands, patients with indication of BB
after coronary artery surgery BB were prescribed in 50.3%
of patients without COPD or asthma, 25.2% of patients with
COPD or asthma on beta-agonists and 12.5% of patients with
severe COPD or asthma [12]. In an analysis of cross-
sectional data from 61 primary care practices (377 439
patients) participating in the Scottish Continuous Morbidity
Recording scheme only 18% of individuals with hearth fail-
ure and COPD were prescribed beta-blockers vs. 41% in
those without COPD [15].Compared with published data form UK and USA our data
suggest that the prescription of BB in patients with heart
disease has doubled in the last decade in both patients with
and without COPD [3,11e15,19]. Caution is needed when
comparisons with other series in different settings and from
different countries are made, nonetheless same trend of
increased use of BB in COPD has been noticed in the
Worcester (Massachusetts) Heart Attack Study cohort [20].
We observed a tendency to prescribe BB to those COPD
patients with worse cardiac function and a history of pre-
vious episodes of LVF (Table 2). Not surprisingly there is a
higher proportion of COPD patients on the beta1-selective
bisoprolol (Fig. 1). However, carvedilol is as frequently used
in COPD patients as in non-COPD patients (Fig. 1) in spite of
the fact that it reduces lung function more than beta1-se-
lective BB [21],. The higher use of angiotensin converting
enzyme inhibitors and diuretics in the BB group are prob-
ably a reflection of worse cardiac function in those with
COPD in which BB are prescribed.
Wewere surprised to find an overall decrease in the use of
long-term BD both LAMA and LABA (Table 4). The reasons for
this are not clear, but the perception that they can interfere
with BB, and non-adherence by patients with several medi-
cations [22], may play a role. Interestingly enough, there is a
decrease in the proportion of patients treated with “tradi-
tional” LABAs in the BB group, in part compensated by an
increase in the use of ultra-LABA. This may show the fear to
prescribe “traditional” LABA by those physiciansmore aware
of cardiac disease managementdthose also more prone to
use BBd since there is some evidence associating “tradi-
tional” LABA to increasedmortality in both patientswith CHF
and with CAD [23e26]. The reduction in the use of “LABA”
results in less inhaled corticosteroids use as well since
“traditional” LABA were almost always prescribed in fixed-
dose combinations in this cohort.
Another interesting finding of this study is that COPD
patients using BB are less symptomatic and have both fewer
exacerbations and fewer exacerbations attended at the ER
in spite of receiving less respiratory medication. Several
factors are related to exacerbations (Table 5), but only
GOLD stage, use of BB, use of LABA (including ultra-LABA)
and comorbidities have independent effects (Table 6).
Anecdotally an HR > 70 bpm was associated to a higher risk
of exacerbations, what may indicate that not only beta-
blockade, but effective beta-blockade is the likely pro-
tective factor.
The relationship between GOLD stage and exacerbations
have been recently described in the ECLIPSE cohort [27]
and our study corroborates that GOLD groups differ in
other aspects apart from those used for their somehow
questionable definition [28]. The association between LABA
and exacerbations attended at the ER is also in keeping
with other observational evidence [3,8,23e25,29] what
together makes necessary and urgent to perform random-
ized trials enrolling patients with significant COPD and CHF
or CAD to determine the risks and benefits of LABA,
particularly in combination with LAMA [8,12]. Meanwhile,
careful use of LABA and short-acting beta2-agonists in COPD
patients with significant cardiac comorbidites is warranted
[8,25,30].
BB had a clear protective effect regarding exacerbations
in COPD patients (Table 6). In a retrospective cohort study
Table 5 Unadjusted OR for factors associated with exacerbations in the COPD group.
Exacerbations (2) Exacerbations(ER)
Variables OR (95% CI) p Variables OR (95% CI) p
GOLD D 3.74 (2.03e6.89) 0.000 GOLD A 0.26 (0.13e0.50) 0.000
mMRC  2 5.30 (2.02e13.89) 0.001 mMRC  2 3.46 (1.89e6.36) 0.000
FEV1% P<50% 2.70 (1.48e4.91) 0.001 FEV1%P<50% 2.74 (1.62e4.62) 0.000
hypolipemiants 0.56 (0.40e0.80) 0.001 GOLD D 3.20 (1.85e5.56) 0.000
BB 0.41 (0.23e0.75) 0.004 BB 0.41 (0.25e0.68) 0.001
CAT  10 5.87 (1.76e19.61) 0.004 CAT  10 3.48 (1.72e7.03) 0.001
GOLD A 0.26 (0.10e0.68) 0.006 LABA þ U 2.69 (1.42e5.12) 0.002
Combinations 2.20 (1.12e4.35) 0.023 Anemia 2.70 (1.54e4.74) 0.001
Diabetes 1.87 (1.03e3.40) 0.039 Combinations 2.10 (1.23e3.56) 0.006
HR  70 bpm 2.09 (1.02e4.29) 0.045 HR  70 bpm 2.18 (1.24e3.82) 0.006
LVEF 1.02 (0.99e1.04) 0.143 A. fibrillation 0.41 (0.21e0.79) 0.008
LABA þ U 1.74 (0.80e3.81) 0.164 LVF 1.92 (1.15e3.20) 0.013
SHT 1.70 (0.80e3.60) 0.168 Diabetes 1.87 (1.12e3.13) 0.017
Ca-antagonist 1.45 (0.80e2.63) 0.217 Antiarrhytmics 1.49 (1.02e2.18) 0.042
LAMA 1.52 (0.73e3.15) 0.259 BMI  30 kg/m2 0.78 (0.47e1.27) 0.313
LVF 1.39 (0.77e2.51) 0.279 LVEF 1.01 (0.99e1.03) 0.446
Active smoker 0.62 (0.25e1.57) 0.315 Female sex 1.33 (0.50e3.57) 0.526
A. fibrillation 0.72 (0.35e1.47) 0.366 AIA 0.85 (0.51e1.42) 0.536
Anemia 1.32 (0.70e2.49) 0.385 GOLD C 0.72 (0.23e2.26) 0.572
AIA 0.78 (0.42e1.45) 0.436 hypolipemiants 1.06 (0.79e1.42) 0.709
GOLD B 0.79 (0.43e1.44) 0.437 Active smoker 1.13 (0.56e2.26) 0.736
BMI  30 kg/m2 0.83 (0.46e1.50) 0.538 LAMA 0.92 (0.52e1.63) 0.780
Antiarrhytmics 1.09 (0.73e1.64) 0.661 GOLD B 0.94 (0.57e1.55) 0.811
Female 1.05 (0.33e3.35) 0.936 Ca-antagonist 0.95 (0.57e1.58) 0.854
GOLD C 0.00 (0.00e0.00) 0.999 SHT 0.95 (0.54e1.69) 0.866
OR: odds ratio,95%IC: ninety-five percent confidence interval, GOLD: GOLD combined assessment stage, mMRC: Medical Research
Council modified scale, FEV1%P<50%: Forced expiratory volume in the first second lower than 50% of predicted, BB: on beta-blocker
treatment, CAT: COPD assessment test, combinations: combinations of LABA þ inhaled corticosteroids, HR: heart rate,, LVEF: left
ventricular ejection fraction, LABA: long-acting beta2 agonist, LABAþ U: use of LABA or ultra-LABA, SHT: systemic arterial hypertension,
Ca-antagonist: calcium channel blockers, LAMA: long acting antimuscarinic agents, LVF: history of left ventricular failure episodes, A.
fibrillation: atrial fibrillation in the ECG, AIA: history of acute ischemic attack, BMI: body mass index; , Female: female sex,.
742 L. Puente-Maestu et al.using a disease specific database of COPD patients (TARDIS)
in Scotland, BB reduced mortality and COPD exacerbations
when added to established inhaled stepwise therapy for
COPD, independently of overt cardiovascular disease and
cardiac drugs [17]. Another retrospective study also showed
a reduction in ER visits or hospitalizations with BB in COPD
patients [31]. Finally BB appears to reduce mortality in
those admitted by acute exacerbations of COPD [13].Table 6 Adjusted OR for factors associated with exacerbations
Exacerbations (2)
Variables OR (95% CI) p
BB 0.26 (0.14e0.50) 0.000
GOLD D 2.64 (1.43e4.93) 0.002
Diabetes 2.04 (1.07e3.91) 0.031
OR: odds ratio,95%IC: ninety-five percent confidence interval, BB: on
group. HR > 70 heart rate >70 bpm LABA: long-acting beta2 agonist,
ventricular failure episodes.Limitations
This is a retrospective study; however, both the use of BB
and exacerbations attended at the ER, as well as the other
explanatory variables, could be obtained with great accu-
racy by interviewing the patients and reviewing medical
records. These records are currently accessible in Spain
from the electronic medical database (at least for thein the COPD group.
Exacerbations (ER)
Variables OR (95% CI) p
BB 0.27 (0.15e0.50) 0.000
GOLD D 2.52 (1.40e4.53) 0.003
HR > 70 2.19 (1.24e3.86) 0.007
LABA þ U 2.18 (1.29e3.68) 0.015
LVF 2.27 (1.19e4.33) 0.012
Diabetes 1.82 (1.08e3.38) 0.048
beta-blocker treatment GOLD: GOLD combined risk assessment
LABA þ U: use of LABA or ultra-LABA, LVF: history of acute left
Beta-blockers use in COPD 743region where patients live). To establish the prevalence of
BB use in non-COPD, participant patients were recruited
from cardiologist outpatient offices. They may represent a
more severe and better controlled population than if they
had been recruited from other settings. It also assured the
most thorough observation of current indications for BB in
cardiac patients as the gold standard to compare with.
Regarding the comparability of COPD using and not using BB
or having or not having exacerbations, we used a nested
design. This design paradigmatically satisfies the study base
principle; however we did not match patients for lung
function, age or any other variable because we wanted to
know, as close as possible, the actual clinical practice, even
at the expense of losing causal strength in the associations
found. Therefore groups resulted slightly statistically
different in some variables. The clinical relevance of most
of such differences do not seem to be great, but they un-
cover the difficulty of controlling all the known and un-
known factors and stresses need for clinical trials in
patients with COPD and CHF or CAD. These clinical trials,
particularly on the safety of bronchodilators already
approved and of widespread use in such patients, will be
difficult to set up though; meanwhile observational evi-
dence, such as that provided by this study, will be the only
available one.Conclusions
The use of BB in COPD patients in Spain is lower than what is
recommended by current guidelines. COPD patients with
CHF or CAD have fewer exacerbations and visits to the ER
and are less symptomatic if they use BB, in spite of worse
cardiac function and less use of long-term BD. GOLD stage
and comorbidities are also risk factors for exacerbations.Acknowledgments
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